登录查看更多内容

Prevention Over Pills? Healthcare’s New Direction

MARIN

Actionable market access intelligence to help biopharma navigate complexity, optimize strategy, and drive success.

发布日期: 2025年2月26日

Major changes are reshaping American healthcare just two weeks into Robert F. Kennedy Jr.'s tenure as HHS Secretary. From mass workforce changes to a fundamental shift toward preventative care, the healthcare landscape is evolving rapidly.

Key developments to watch:

FDA reinstating 180+ medical staff after industry pushback
New focus on alternative medicine and preventative approaches
Significant shifts in how user fee-funded programs operate

Changing dynamics between traditional pharma and alternative health sectors

Want to understand what these changes mean for healthcare policy and delivery? Read the full analysis here.

Oncology Access Navigator

146 位关注者

要查看或添加评论，请登录

MARIN的更多文章

2025年3月12日

The $880 Billion Question

The battle over Medicaid's future is heating up in Washington, and the numbers tell an fascinating story. The House…
2025年3月10日

Oncology’s PA Puzzle: Who Appeals, Who Doesn’t, and Why It Matters

Prior authorization (PA) denials are a constant challenge in oncology—but not all providers respond the same way. Some…
2025年3月5日

The Silent Shift in Health Care Rulemaking

In a surprising move, HHS just ended a 50-year practice of public participation in rulemaking. While Medicare/Medicaid…

3 条评论
2025年2月25日

New Analysis: Preparing Your Provider Strategy for Medicare Price Negotiations

As your team prepares for Medicare drug price negotiations, understanding the downstream impact on provider economics…
2025年2月20日

Data-Backed Strategies to Help Manufacturers Engage Oncologists Effectively

More than 50% of community oncology practices report frustration with uncoordinated manufacturer communications. The…
2025年2月19日

The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)

In Part 2 of the Behind the Bill on the nondelegation doctrine, Katie Hayes, MJ draws parallels between the 1930s New…
2025年2月12日

The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)

Just months after overturning the Chevron doctrine—the rule that gave deference to administrative agencies to interpret…
2025年2月6日

Elevate Your Oncology Strategy with the IDN Dataset

Now that 2025 is underway, reconnecting with your key oncology accounts is essential. But, to truly make an impact, you…
2025年2月5日

Fact Check: Trump’s Executive Order & Medicare Drug Costs

Did President Trump really sign an executive order that could increase drug costs for Medicare beneficiaries? And on…
2025年1月30日

From AMCs to Community Clinics: The Future of CAR Ts and Bispecifics

Access to cutting-edge cancer therapies like CAR Ts and bispecific antibodies (BsAbs) is often limited to academic…

See all articles

Oncology Access Navigator

146 位关注者

MARIN的更多文章

The $880 Billion Question

Oncology’s PA Puzzle: Who Appeals, Who Doesn’t, and Why It Matters

The Silent Shift in Health Care Rulemaking

New Analysis: Preparing Your Provider Strategy for Medicare Price Negotiations

Data-Backed Strategies to Help Manufacturers Engage Oncologists Effectively

The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)

The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)

Elevate Your Oncology Strategy with the IDN Dataset

Fact Check: Trump’s Executive Order & Medicare Drug Costs

From AMCs to Community Clinics: The Future of CAR Ts and Bispecifics